<DOC>
	<DOC>NCT00494234</DOC>
	<brief_summary>The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.</brief_summary>
	<brief_title>Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
	<criteria>Advanced breast cancer with positive BRCA1 or BRCA2 status Failed at least one prior chemotherapy In investigators opinion, no curative standard therapy exists Measurable disease Brain metastases Less than 28 days since last treatment used to treat the disease Considered a poor medical risk due to a serious uncontrolled disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Poly(ADP ribose) polymerases</keyword>
	<keyword>AZD2281,KU-0059436 (olaparib)</keyword>
	<keyword>BRCA1 protein</keyword>
	<keyword>BRCA2 protein</keyword>
</DOC>